Brightpath Biotherapeutics submitted an IND application to the FDA to begin a phase I U.S. trial of BP-2202 for multiple myeloma. The filing is tied to NCT07667868 and marks the next step in bringing the company’s program into clinical evaluation. For investors and partners, the IND start provides an early readout pathway for safety, tolerability, and preliminary pharmacology ahead of later-stage trials.